Search Database ICD-O-3 Code Lists

Name

Acute myeloid leukemia with t(6;9)(p23;q34.1); DEK-NUP214

ICD-O-3 Morphology

9865/3: Acute myeloid leukemia with t(6;9)(p23;q34);DEK-NUP214
Effective 2010 and later

Reportable

for cases diagnosed 2010 and later

Primary Site(s)

C421
Primary site must be bone marrow (C421)

Coding Manual: Hematopoietic Coding Manual (PDF)

Abstractor Notes

(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see code 9861/3.)

This AML has a generally poor prognosis. Elevated white blood cell counts are most predictive of shorter overall survival and increased BM blasts are associated with shorter free survival. Very limited data available regarding treatment or survival.

In adults the WBC is generally lower than other AML types. The BM may have morphologic and cytochemical features of any FAB subtype of AML other than acute promyelocytic leukemia and acute megakaryoblastic leukemia.

If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.

Diagnostic Confirmation

This AML is part of the "AML with recurrent genetic abnormalities" group. Since this AML is diagnosed based on genetics, diagnostic confirmation will always be 3.

Grade

Not Applicable

Module Rule

See abstractor notes

Alternate Names

Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214

Definition

Acute myeloid leukemia with t(6;9)(p23;q34.1) resulting in DEK-NUP214 is an AML with greater than or equal to 20% peripheral blood or bone marrow blasts with or without monocytic features. It is often associated with basophilia and multilineage dysplasia.

Definitive Diagnostic Methods

Bone marrow biopsy
Genetic testing
Immunophenotyping

Genetics Data

DEK-NUP214
FLT3-ITD
NUP214 (also called CAN) on chromosome 9

Immunophenotyping

CD9+ (expression/positive)
CD13+ (expression/positive)
CD15+ (expression/positive)
CD33+ (expression/positive)
CD34+ (expression/positive)
CD38+ (expression/positive)
CD64+ (expression/positive)
CD123+ (expression/positive)
HLA-DR-(no expression/negative)
KIT (CD117)
MPO+ (expression/positive)

Treatments

Hematologic Transplant and/or Endocrine Procedures

Transformations to

None

Transformations from

Same Primaries

Corresponding ICD-9 Codes

205.0 Acute myeloid leukemia

Corresponding ICD-10 Codes

C92.0 Acute myeloid leukemia

Corresponding ICD-10-CM Codes (U.S. only)

C92.0 Acute myeloblastic leukemia (effective October 01, 2015)

Signs and Symptoms

Anemia
Easy bruising or bleeding
Fatigue
Fever
Pancytopenia
Petechiae
Shortness of breath
Thrombocytopenia
Weakness
Weight loss or loss of appetite

Diagnostic Exams

Bone marrow aspiration and biopsy
CT (CAT) scan
Cytogenetic analysis
Immunophenotyping
Lumbar puncture
Peripheral blood smear
Physical exam and history

Progression and Transformation

Elevated white blood cell counts associated with shorter overall survival
Increased bone marrow blasts associated shorter disease-free survival

Epidemiology and Mortality

Age: 13 years median age in children, 35 years median age in adults
Incidence: 0.7-1.8% of AML cases
Survival: poor prognosis for both children and adults

Sources

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 137-138

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577

National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Glossary